X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-28 | SLDB | Solid Biosciences Inc. | Ganot Ilan | Dir | S - Sale+OE | $6.59 | -191 | 136,167 | 0% | -$1,259 | |||||
| M | 2026-01-28 | ELUT | Elutia Inc. | Neels Guido J | Dir | P - Purchase | $1.06 | +30,000 | 98,750 | +44% | +$31,800 | |||||
2026-01-28 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $139.89 | -10,000 | 556,698 | -2% | -$1,398,911 | ||||||
| M | 2026-01-27 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $7.72 | -21,581 | 420,047 | -5% | -$166,677 | |||||
| M | 2026-01-27 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $7.71 | -13,038 | 276,610 | -5% | -$100,473 | |||||
| M | 2026-01-27 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $7.71 | -15,515 | 249,301 | -6% | -$119,631 | |||||
| DM | 2026-01-26 | ABOS | Acumen Pharmaceuticals, Inc. | Meisner Derek M | GC, Corp Sec | S - Sale+OE | $3.00 | -17,756 | 173,999 | -9% | -$53,280 | |||||
2026-01-26 | ZIVO | Zivo Bioscience, Inc. | Cornell Alison A | Dir | P - Purchase | $8.54 | +11,709 | 279,481 | +4% | +$99,995 | ||||||
2026-01-26 | ZIVO | Zivo Bioscience, Inc. | Payne John Bernard | Pres, CEO | P - Purchase | $8.54 | +11,709 | 19,618 | +148% | +$99,995 | ||||||
2025-04-03 | CRSP | Crispr Therapeutics AG | Patel Naimish | Chief Medical Officer | P - Purchase | $32.96 | +1,508 | 1,508 | New | +$49,704 | ||||||
2026-01-14 | ZIVO | Zivo Bioscience, Inc. | Maggiore Christopher D. | Dir, 10% | P - Purchase | $8.49 | +1,766 | 519,292 | 0% | +$14,993 | ||||||
2026-01-14 | ZIVO | Zivo Bioscience, Inc. | Yaldoo Laith L | Dir, 10% | P - Purchase | $8.49 | +1,766 | 579,638 | 0% | +$14,993 | ||||||
| M | 2026-01-23 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D | S - Sale | $4.72 | -116,050 | 1,317,389 | -8% | -$547,469 | |||||
2026-01-23 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $44.91 | -2,390 | 310,493 | -1% | -$107,330 | ||||||
| M | 2026-01-23 | TSHA | Taysha Gene Therapies, Inc. | Nolan Sean P. | CEO | S - Sale | $4.72 | -178,101 | 4,443,802 | -4% | -$840,196 | |||||
| M | 2026-01-23 | TSHA | Taysha Gene Therapies, Inc. | Alam Kamran | CFO | S - Sale | $4.72 | -102,817 | 1,443,786 | -7% | -$485,042 | |||||
| D | 2026-01-23 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale+OE | $135.00 | -115,640 | 566,698 | -17% | -$15,611,400 | |||||
| D | 2026-01-22 | CRSP | Crispr Therapeutics AG | Prasad Raju | CFO | S - Sale+OE | $60.19 | -34,972 | 6,767 | -84% | -$2,104,965 | |||||
| D | 2026-01-22 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Finance | S - Sale+OE | $45.52 | -5,000 | 12,965 | -28% | -$227,612 | |||||
2026-01-22 | BEAM | Beam Therapeutics Inc. | Cavanagh Bethany J | SVP, Finance, Treasurer | S - Sale | $35.00 | -6,198 | 34,813 | -15% | -$216,933 | ||||||
2026-01-22 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale | $34.00 | -1,371 | 95,667 | -1% | -$46,614 | ||||||
2026-01-22 | CVM | Cel Sci Corp | Kersten Geert R | CEO | P - Purchase | $5.26 | +38,023 | 120,815 | +46% | +$200,001 | ||||||
| M | 2026-01-21 | ABOS | Acumen Pharmaceuticals, Inc. | Meisner Derek M | GC, Corp Sec | S - Sale | $1.87 | -8,934 | 173,999 | -5% | -$16,721 | |||||
| M | 2026-01-21 | ABOS | Acumen Pharmaceuticals, Inc. | Siemers Eric | Chief Medical Officer | S - Sale | $1.81 | -3,226 | 255,371 | -1% | -$5,833 | |||||
| M | 2026-01-21 | ABOS | Acumen Pharmaceuticals, Inc. | Zuga Matt | CFO, Chief Business Officer | S - Sale | $1.83 | -4,160 | 304,924 | -1% | -$7,607 | |||||
| M | 2026-01-21 | ABOS | Acumen Pharmaceuticals, Inc. | Oconnell Daniel Joseph | CEO | S - Sale | $1.83 | -12,035 | 881,275 | -1% | -$21,993 | |||||
| M | 2026-01-21 | ABOS | Acumen Pharmaceuticals, Inc. | Barton Russell | COO | S - Sale | $1.81 | -2,777 | 205,092 | -1% | -$5,031 | |||||
2026-01-22 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $12.30 | -4,000 | 128,635 | -3% | -$49,200 | ||||||
2026-01-21 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $115.60 | -908 | 46,976 | -2% | -$104,965 | ||||||
2026-01-22 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $46.71 | -14,898 | 85,660 | -15% | -$695,938 | ||||||
2026-01-21 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $26.03 | -1,977 | 197,634 | -1% | -$51,461 | ||||||
2026-01-21 | ALLO | Allogene Therapeutics, Inc. | Roberts Zachary | EVP of R, D | S - Sale | $1.56 | -26,269 | 616,866 | -4% | -$40,980 | ||||||
| D | 2026-01-22 | APGE | Apogee Therapeutics, Inc. | Fairmount Funds Management LLC | Dir | S - Sale+OE | $76.30 | -1,750,000 | 400,979 | -81% | -$133,525,000 | |||||
| D | 2026-01-20 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | Dir | S - Sale+OE | $4.47 | -40,000 | 913,839 | -4% | -$178,800 | |||||
| D | 2026-01-22 | DTIL | Precision Biosciences Inc | Amoroso Michael | Pres, CEO | S - Sale+OE | $4.17 | -34,799 | 196,154 | -15% | -$145,112 | |||||
| D | 2026-01-21 | DTIL | Precision Biosciences Inc | Scimeca Dario | GC, Secretary | S - Sale+OE | $4.03 | -8,854 | 44,715 | -17% | -$35,682 | |||||
| D | 2026-01-21 | DTIL | Precision Biosciences Inc | Kelly John Alexander | CFO | S - Sale+OE | $4.03 | -15,213 | 106,448 | -13% | -$61,308 | |||||
| D | 2026-01-21 | DTIL | Precision Biosciences Inc | Smith J. Jefferson | Chief Research Officer | S - Sale+OE | $4.03 | -10,200 | 118,115 | -8% | -$41,106 | |||||
| M | 2026-01-20 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale | $57.40 | -90,000 | 219,823 | -29% | -$5,166,298 | |||||
| D | 2026-01-20 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $8.92 | -972 | 8,321 | -10% | -$8,667 | |||||
2026-01-20 | IBRX | Immunitybio, Inc. | Simon Barry J. | Dir | S - Sale | $7.20 | -151,967 | 3,091,604 | -5% | -$1,094,297 | ||||||
| DM | 2026-01-16 | IBRX | Immunitybio, Inc. | Selecky Christobel | Dir | S - Sale+OE | $5.84 | -75,000 | 0 | -100% | -$437,650 | |||||
2026-01-16 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $44.48 | -8,406 | 100,558 | -8% | -$373,880 | ||||||
2026-01-16 | SRRK | Scholar Rock Holding Corp | Parlavecchio Caryn | CHRO | S - Sale | $44.48 | -6,600 | 148,864 | -4% | -$293,553 | ||||||
2026-01-16 | SRRK | Scholar Rock Holding Corp | Marantz Jing L. | Chief Medical Officer | S - Sale | $44.48 | -5,798 | 95,687 | -6% | -$257,882 | ||||||
2026-01-16 | SRRK | Scholar Rock Holding Corp | Ho Junlin | GC | S - Sale | $44.48 | -8,016 | 214,553 | -4% | -$356,533 | ||||||
2026-01-21 | CABA | Cabaletta Bio, Inc. | Chang David J. | Chief Medical Officer | P - Purchase | $2.26 | +8,800 | 8,800 | New | +$19,888 | ||||||
2026-01-21 | CABA | Cabaletta Bio, Inc. | Binder Gwendolyn | Pres, Science, Tech. | P - Purchase | $2.19 | +11,312 | 31,312 | +57% | +$24,763 | ||||||
2026-01-21 | CABA | Cabaletta Bio, Inc. | Tomasello Shawn | Dir | P - Purchase | $2.21 | +22,725 | 22,725 | New | +$50,322 | ||||||
2026-01-21 | CABA | Cabaletta Bio, Inc. | Gavel Steve | CHIEF COMMERCIAL OFFICER | P - Purchase | $2.27 | +22,170 | 22,170 | New | +$50,215 | ||||||
2026-01-21 | CABA | Cabaletta Bio, Inc. | Bollard Catherine | Dir | P - Purchase | $2.27 | +4,405 | 5,405 | +441% | +$9,982 | ||||||
2026-01-21 | CABA | Cabaletta Bio, Inc. | Nichtberger Steven | Pres, CEO | P - Purchase | $2.24 | +45,000 | 1,394,483 | +3% | +$100,778 | ||||||
2026-01-21 | CABA | Cabaletta Bio, Inc. | Simon Mark | Dir | P - Purchase | $2.28 | +11,061 | 154,205 | +8% | +$25,261 | ||||||
2026-01-21 | CABA | Cabaletta Bio, Inc. | Gerard Michael | GC | P - Purchase | $2.27 | +6,600 | 6,600 | New | +$14,979 | ||||||
| M | 2026-01-20 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.33 | +900 | 268,866 | 0% | +$1,194 | |||||
| D | 2026-01-20 | GILD | Gilead Sciences, Inc. | Bluestone Jeffrey | Dir | S - Sale+OE | $123.50 | -5,000 | 8,920 | -36% | -$617,500 | |||||
2026-01-16 | PALI | Palisade Bio, Inc. | Williams Donald Allen | Dir | P - Purchase | $1.67 | +5,000 | 13,728 | +57% | +$8,356 | ||||||
2026-01-20 | BEAM | Beam Therapeutics Inc. | Cavanagh Bethany J | SVP, Finance, Treasurer | S - Sale | $30.12 | -3,034 | 41,011 | -7% | -$91,384 | ||||||
| D | 2026-01-20 | ACLX | Arcellx, Inc. | Lubner David Charles | Dir | S - Sale+OE | $75.00 | -6,000 | 21,659 | -22% | -$450,000 | |||||
| M | 2026-01-15 | SRZN | Surrozen, Inc./De | Column Group III Gp, LP | 10% | P - Purchase | $19.74 | +32,507 | 2,261,777 | +1% | +$641,597 | |||||
| M | 2026-01-15 | SRZN | Surrozen, Inc./De | Kutzkey Tim | Dir, 10% | P - Purchase | $19.74 | +32,507 | 2,261,777 | +1% | +$641,597 | |||||
| D | 2026-01-16 | NBIX | Neurocrine Biosciences Inc | Gano Kyle | CEO | S - Sale+OE | $132.71 | -36,400 | 140,407 | -21% | -$4,830,458 | |||||
2026-01-20 | AURA | Aura Biosciences, Inc. | Elazzouzi Amy | SVP, Finance | S - Sale | $4.86 | -1,581 | 84,081 | -2% | -$7,684 | ||||||
2026-01-20 | AURA | Aura Biosciences, Inc. | De Los Pinos Elisabet | See Remarks | S - Sale | $4.86 | -16,928 | 585,226 | -3% | -$82,270 | ||||||
| D | 2026-01-20 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | S - Sale+OE | $67.91 | -5,500 | 0 | -100% | -$373,521 | |||||
2026-01-15 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale | $34.61 | -18,629 | 97,038 | -16% | -$644,832 | ||||||
2026-01-14 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $81.11 | -20,000 | 1,192,987 | -2% | -$1,622,159 | ||||||
| D | 2026-01-14 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $45.20 | -13,112 | 108,964 | -11% | -$592,611 | |||||
2026-01-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $124.31 | -3,000 | 150,503 | -2% | -$372,930 | ||||||
2026-01-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale | $124.31 | -3,000 | 103,221 | -3% | -$372,930 | ||||||
2026-01-16 | CCCC | C4 Therapeutics, Inc. | Reyno Leonard | Chief Medical Officer | S - Sale | $2.22 | -10,000 | 156,382 | -6% | -$22,200 | ||||||
2026-01-13 | SRRK | Scholar Rock Holding Corp | Sinha Vikas | CFO | S - Sale | $42.70 | -16,755 | 583,245 | -3% | -$715,439 | ||||||
2026-01-13 | SRRK | Scholar Rock Holding Corp | Woods Keith | COO | S - Sale | $42.70 | -16,746 | 583,254 | -3% | -$715,054 | ||||||
2026-01-13 | SRRK | Scholar Rock Holding Corp | Vaishnaw Akshay | Pres of R, D | S - Sale | $42.70 | -20,438 | 595,767 | -3% | -$872,703 | ||||||
2026-01-13 | SRRK | Scholar Rock Holding Corp | Hallal David | CEO | S - Sale | $42.70 | -57,450 | 1,746,645 | -3% | -$2,453,115 | ||||||
2026-01-13 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $40.00 | -3,000 | 137,031 | -2% | -$120,000 | ||||||
| D | 2026-01-13 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale+OE | $40.00 | -23,279 | 312,883 | -7% | -$931,160 | |||||
| M | 2026-01-13 | SRZN | Surrozen, Inc./De | Kutzkey Tim | Dir, 10% | P - Purchase | $19.86 | +17,993 | 2,229,270 | +1% | +$357,353 | |||||
| M | 2026-01-13 | SRZN | Surrozen, Inc./De | Column Group III Gp, LP | 10% | P - Purchase | $19.86 | +17,993 | 2,229,270 | +1% | +$357,353 | |||||
2026-01-12 | ATRA | Atara Biotherapeutics, Inc. | Panacea Innovation Ltd | 10% | S - Sale | $6.07 | -80,554 | 1,373,182 | -6% | -$489,019 | ||||||
| M | 2026-01-12 | DVLT | Datavault Ai Inc. | Scilex Holding Co | 10% | S - Sale | $0.83 | -15,965,541 | 213,766,229 | -7% | -$13,215,896 | |||||
| D | 2026-01-12 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $17.73 | -79,590 | 318,478 | -20% | -$1,411,131 | |||||
2026-01-14 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale | $68.51 | -5,882 | 23,749 | -20% | -$402,997 | ||||||
| D | 2026-01-12 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale+OE | $18.00 | -4,290 | 216,637 | -2% | -$77,220 | |||||
| D | 2026-01-12 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D | S - Sale+OE | $4.71 | -200,000 | 1,433,439 | -12% | -$942,000 | |||||
2026-01-09 | PALI | Palisade Bio, Inc. | Williams Donald Allen | Dir | P - Purchase | $1.88 | +5,000 | 8,728 | +134% | +$9,400 | ||||||
2026-01-13 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale | $65.51 | -7,437 | 29,631 | -20% | -$487,213 | ||||||
| D | 2026-01-13 | SLDB | Solid Biosciences Inc. | Tan Kevin | CFO, Treasurer | S - Sale+OE | $5.27 | -5,704 | 46,100 | -11% | -$30,060 | |||||
| D | 2026-01-09 | CGON | Cg Oncology, Inc. | Mulay James | Dir | S - Sale+OE | $52.47 | -11,145 | 0 | -100% | -$584,799 | |||||
2026-01-09 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $35.26 | -2,738 | 140,031 | -2% | -$96,545 | ||||||
2026-01-12 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale | $64.15 | -6,131 | 37,068 | -14% | -$393,286 | ||||||
2026-01-08 | ABOS | Acumen Pharmaceuticals, Inc. | Zuga Matt | CFO, Chief Business Officer | S - Sale | $1.82 | -6,888 | 209,951 | -3% | -$12,513 | ||||||
2026-01-08 | ABOS | Acumen Pharmaceuticals, Inc. | Barton Russell | COO | S - Sale | $1.86 | -3,530 | 123,269 | -3% | -$6,562 | ||||||
| M | 2026-01-08 | ABOS | Acumen Pharmaceuticals, Inc. | Meisner Derek M | GC, Corp Sec | S - Sale | $1.80 | -50,659 | 83,800 | -38% | -$91,073 | |||||
| M | 2026-01-08 | ABOS | Acumen Pharmaceuticals, Inc. | Oconnell Daniel Joseph | CEO | S - Sale | $1.77 | -26,472 | 593,510 | -4% | -$46,954 | |||||
2026-01-09 | FATE | Fate Therapeutics Inc | Tahl Cindy | See Remarks | S - Sale | $1.06 | -10,589 | 387,081 | -3% | -$11,275 | ||||||
| D | 2026-01-08 | PASG | Passage Bio, Inc. | Chou William | Pres, CEO | S - Sale+OE | $18.44 | -4,076 | 6,524 | -38% | -$75,159 | |||||
2026-01-09 | FATE | Fate Therapeutics Inc | Valamehr Bahram | Pres, CEO | S - Sale | $1.07 | -5,190 | 329,708 | -2% | -$5,557 | ||||||
| D | 2026-01-08 | PASG | Passage Bio, Inc. | Borthwick Kathleen | CFO | S - Sale+OE | $18.44 | -2,062 | 5,402 | -28% | -$38,022 | |||||
| D | 2026-01-07 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $77.84 | -18,700 | 212,523 | -8% | -$1,455,613 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |